Objective: The aim of the present retrospective pilot study was to examine the clinical impact
of the cytochrome P450 (CYP) enzyme CYP2D6 poor metabolizer (PM) genotype in patients …

Study Objective. To investigate whether a relationship exists between the most common
known cytochrome P450 (CYP) isozyme 2D6 mutations and schizophrenia. Because most …

Objective: In order to evaluate whether poor metabolizers (PM) of debrisoquine are
overrepresented among patients with acute dystonic reactions and chronic movement …

There is wide variability in the response of individuals to standard doses of antipsychotic
drugs. It has been suggested that this may be partly explained by differences in the …

The CYP2D6 gene is highly polymorphic, causing absent (poor metabolizers), decreased,
normal or increased enzyme activity (extensive and ultrarapid metabolizers). The genetic …

Antipsychotic drugs are used for the treatment of schizophrenia and other related psychotic
disorders. The antipsychotics currently available include older or classical compounds and …

The polymorphic isoenzyme CYP2D6 has a major role in the oxidative metabolism of many
deal of psychoactive drugs. Its six mutant alleles (null alleles* 3,* 4,* 5,* 6,* 7 and* 8) encode …

Poor response to antipsychotics treatment and extrapyramidal side effects (EPS) are the
most challenging problems in the treatment of schizophrenia. Several studies were …

Antipsychotic metabolism cosegregates with the polymorphic cytochrome P4502D6
(CYP2D6) hepatic enzyme. Approximately 5-10% of Caucasians show impaired metabolism …

Aims: The delineation of allele distribution and frequency is required to effectively translate
pharmacogenetics to the clinic and given the paucity of CYP2D6 data in the Brazilian …